Osteoclast Inhibitory Lectin, an Immune Cell Product That Is Required for Normal Bone Physiology in Vivo
Vicky Kartsogiannis(Monash Institute of Medical Research), Matthew T. Gillespie(Hudson Institute of Medical Research), Ingrid J. Poulton(St Vincents Institute of Medical Research), T. John Martin(The Open University), Mark J. Smyth(Peter MacCallum Cancer Centre), Kong Wah Ng(St Vincent's Hospital Melbourne), Natalie A. Sims(The University of Melbourne), Morgan E. Wallace(Peter MacCallum Cancer Centre), Mirijana Cipetić(St Vincents Institute of Medical Research), Hasnawati Saleh(Hasanuddin University), Chi Ly(The University of Melbourne), J Quinn(The University of Melbourne), Hong Zhou(California NanoSystems Institute), Narelle E. McGregor(St. Vincent's Medical Center), Emma C. Walker(Washington University in St. Louis)
Cited by 37
Related Papers
Modulation of Osteoclast Differentiation and Function by the New Members of the Tumor Necrosis Factor Receptor and Ligand Families
|Endocrine Reviews|1999|2.3k
IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis
|Journal of Clinical Investigation|1999|1.7k
Immune surveillance of tumors
|Journal of Clinical Investigation|2007|1.4k
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
|Annals of Oncology|2014|1.3k
OSTEOBLASTIC CELLS ARE INVOLVED IN OSTEOCLAST FORMATION
|Endocrinology|1988|945